This study assessed the metabolic effects of aripiprazole and pimozide in pediatric Tourette
syndrome, a neurodevelopmental condition characterized by multiple motor and phonic tics.
Patients receiving aripiprazole (n= 25) or pimozide (n= 25) were compared with medication-
free patients (n= 25). Body mass index, glycemia, triglyceridemia, and cholesterolemia were
monitored at baseline and 12 and 24 months after commencing treatment. The aripiprazole
group demonstrated significant increases in cholesterolemia. The pimozide group …